Prior Dengue Virus Exposure is Associated with Enhanced Zika Virus-Specific ADCC Activity in a Longitudinal Human Cohort
Clicks: 1
ID: 325610
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #427 of 430 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 430 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Prior dengue virus (DENV) infection is common in regions affected by Zika virus (ZIKV) and may shape immune responses to subsequent ZIKV infection. Although cross-reactive neutralizing and disease-enhancing antibodies have been extensively studied, the effect of prior DENV immunity on antibody-dependent cellular cytotoxicity (ADCC) responses to ZIKV remains unclear. METHODS: Longitudinal serum samples were obtained and analyzed from a prospective cohort of 46 PCR-confirmed ZIKV cases enrolled at two U.S. sites between 2016-2018 (follow-up visits 6-409 days). ZIKV cases were classified as DENV-experienced (n=13) or DENV-naïve groups (n=33) based on detection of DENV neutralizing antibodies at baseline. ZIKV-specific ADCC activity was measured using a natural killer cell cytotoxicity assay. RESULTS: DENV-experienced individuals had significantly higher peak ZIKV-specific ADCC responses (geometric mean titers [GMT] 15,104 vs 1,819; P<0.0001) and greater cumulative ADCC responses during early (≤80 days, AUC 918,540 vs 42,752; P = 0.0012) and late convalescent phases (>80 days, AUC 953,694 vs 182,004; P=0.0037). Peak ZIKV ADCC magnitude did not correlate with peak DENV or ZIKV antibody neutralizing titers, and ZIKV neutralization efficiency at the time of peak ZIKV ADCC did not differ between groups. However, ZIKV ADCC normalized to ZIKV IgG was significantly higher among DENV-experienced individuals (GMT 2,230 vs 735.6; P=0.0107). CONCLUSIONS: Prior DENV infection was associated with greater ZIKV-specific ADCC magnitude, despite similar ZIKV neutralization, suggesting that prior DENV exposure shapes Fc-mediated flavivirus immunity beyond neutralization. Future studies are needed to assess the clinical implications of these antibodies in immunopathology and protection.
| Reference Key |
openalex_W7203737910
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jessica N. McCaffery, Xuemin Chen, Theda Gibson, Muktha S. Natrajan, Lilin Lai, Wendy A. Keitel, Nadine Rouphael, Larry J. Anderson, Evan J. Anderson, Mark J. Mulligan, Hana M. El Sahly, Christina A. Rostad |
| Journal | The Journal of infectious diseases |
| Year | 2026 |
| DOI |
10.1093/infdis/jiag429
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.